Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerativ...
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-nega...
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, announced results from an independent evaluation of myStage Dx, its CE-IVD...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for t...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced that it has received full regulato...
Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care f...
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansi...
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (E...
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedente...
Managing motor fluctuations and dyskinesia remains a significant challenge for people living with advanced Parkinson's disease, despite advances in existin...
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the first patient has been dosed in an open-label, m...
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing...
© 2026 Biopharma Boardroom. All Rights Reserved.
